Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–10. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• White MK, Pagano JS, Khalili K. Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev. 2014;27(3):463–481. doi:10.1128/CMR.00124-13.
   PubMed Web of Science ®Google Scholar
• Luo GG, Ou JH. Oncogenic viruses and cancer. Virol Sin. 2015;30(2):83–84. doi:10.1007/s12250-015-3599-y.
   PubMed Web of Science ®Google Scholar
• Teixeira AA, Marchiò S, Dias‐Neto E, Nunes DN, Da Silva IT, Chackerian B, Barry M, Lauer RC, Giordano RJ, Sidman RL, et al. Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses. EMBO Mol Med. 2017;9(10):1327–1330. doi:10.15252/emmm.201708072.
   PubMed Web of Science ®Google Scholar
• Saez-Cirion A, Manel N. Immune Responses to Retroviruses. Annu Rev Immunol. 2018;36(1):193–220. doi:10.1146/annurev-immunol-051116-052155.
   PubMed Web of Science ®Google Scholar
• Albanese M, Tagawa T, Buschle A, Hammerschmidt W. MicroRNAs of Epstein-Barr virus control innate and adaptive antiviral immunity. J Virol. 2017;91(16). doi:10.1128/JVI.01667-16.
   PubMed Web of Science ®Google Scholar
• Siriwardena SU, Chen K, Bhagwat AS. Functions and malfunctions of mammalian DNA-Cytosine deaminases. Chem Rev. 2016;116(20):12688–12710. doi:10.1021/acs.chemrev.6b00296.
   PubMed Web of Science ®Google Scholar
• Seplyarskiy VB, Soldatov RA, Popadin KY, Antonarakis SE, Bazykin GA, Nikolaev SI. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. Genome Res. 2016;26(2):174–182. doi:10.1101/gr.197046.115.
   PubMed Web of Science ®Google Scholar
• Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R, Klimczak L, Kryukov G, Malc E, Mieczkowski P, et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell. 2012;46(4):424–435. doi:10.1016/j.molcel.2012.03.030.
   PubMed Web of Science ®Google Scholar
• Swanton C, McGranahan N, Starrett GJ, Harris RS, Enzymes: APOBEC, Enzymes: APOBEC, Enzymes: APOBEC. Mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 2015;5(7):704–712. doi:10.1158/2159-8290.CD-15-0344.
   PubMed Web of Science ®Google Scholar
• Wang S, Jia M, He Z, Liu XS. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene. 2018;37(29):3924–3936. doi:10.1038/s41388-018-0245-9.
   PubMed Web of Science ®Google Scholar
• Bobrovnitchaia I, Valieris R, Drummond RD, Lima JP, Freitas HC, Bartelli TF, Amorim MG, Nunes DN, Dias‐Neto E, Silva IT, et al. APOBEC-mediated DNA alterations: a possible new mechanism of carcinogenesis in EBV-positive gastric cancer. Int J Cancer. 2020;146(1):181–191. doi:10.1002/ijc.32411.
   PubMed Web of Science ®Google Scholar
• Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45(9):970–976. doi:10.1038/ng.2702.
   PubMed Web of Science ®Google Scholar
• Koito A, Ikeda T. Intrinsic immunity against retrotransposons by APOBEC cytidine deaminases. Front Microbiol. 2013;4:28. doi:10.3389/fmicb.2013.00028.
   PubMed Web of Science ®Google Scholar
• Venkatesan S, Rosenthal R, Kanu N, McGranahan N, Bartek J, Quezada SA, Hare J, Harris RS, Swanton C. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann Oncol. 2018;29(3):563–572. doi:10.1093/annonc/mdy003.
   PubMed Web of Science ®Google Scholar
• Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013;494(7437):366–370. doi:10.1038/nature11881.
   PubMed Web of Science ®Google Scholar
• Wang D, Li X, Li J, Lu Y, Zhao S, Tang X, Chen X, Li J, Zheng Y, Li S, et al. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut. 2019;68(10):1846–1857. doi:10.1136/gutjnl-2018-317601.
   PubMed Web of Science ®Google Scholar
• Roper N, Gao S, Maity TK, Banday AR, Zhang X, Venugopalan A, Cultraro CM, Patidar R, Sindiri S, Brown A-L, et al. APOBEC mutagenesis and Copy-Number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors. Cell Rep. 2019;26(10):2651–2666 e2656. doi:10.1016/j.celrep.2019.02.028.
   PubMed Web of Science ®Google Scholar
• Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013;73(24):7222–7231. doi:10.1158/0008-5472.CAN-13-1753.
   PubMed Web of Science ®Google Scholar
• Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, Kobayashi M, Kadowaki N, Takaori-Kondo A. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep. 2012;2(1):806. doi:10.1038/srep00806.
   PubMed Web of Science ®Google Scholar
• Serebrenik AA, Argyris PP, Jarvis MC, Brown WL, Bazzaro M, Vogel RI, Erickson BK, Lee S-H, Goergen KM, Maurer MJ, et al. The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer. Clin Cancer Res. 2020;26(13):3397–3407. doi:10.1158/1078-0432.CCR-19-2786.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wei W, Jin HC, Ying RC, Zhu AK, Zhang FJ. The roles of APOBEC3B in gastric cancer. Int J Clin Exp Pathol. 2015;8:5089–5096.
   PubMed Web of Science ®Google Scholar
• Sieuwerts AM, Willis S, Burns MB, Look MP, Gelder MEMV, Schlicker A, Heideman MR, Jacobs H, Wessels L, Leyland-Jones B, et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer. 2014;5(6):405–413. doi:10.1007/s12672-014-0196-8.
   PubMed Web of Science ®Google Scholar
• Cescon DW, Haibe-Kains B, Mak TW. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A. 2015;112(9):2841-2846. doi:10.1073/pnas.1424869112.
   Google Scholar
• Sieuwerts AM, Schrijver WA, Dalm SU, et al. Progressive APOBEC3B mRNA expression in distant breast cancer metastases. PLoS One. 2017;12(1):e0171343. doi:10.1371/journal.pone.0171343.
   PubMed Web of Science ®Google Scholar
• Nikkila J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, et al. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Br J Cancer. 2017;117(1):113–123. doi:10.1038/bjc.2017.133.
   PubMed Web of Science ®Google Scholar
• Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME, Sweep FCGJ, et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Science Advances. 2016;2(10):e1601737. doi:10.1126/sciadv.1601737.
   PubMed Web of Science ®Google Scholar
• Cao Y, Liu H, Li H, Lin C, Li R, Wu S, Zhang H, He H, Zhang W, Xu J, et al. Association of O6-Methylguanine-DNA Methyltransferase protein expression with postoperative prognosis and adjuvant chemotherapeutic benefits among patients with stage II or III gastric cancer. JAMA Surg. 2017;152(11):e173120. doi:10.1001/jamasurg.2017.3120.
   PubMed Web of Science ®Google Scholar
• Cao Y, He H, Li R, Liu X, Chen Y, Qi Y, Yu K, Wang J, Lin C, Liu H, et al. Latency-associated peptide identifies immunoevasive subtype gastric cancer with poor prognosis and inferior chemotherapeutic responsiveness. Ann Surg. 2020. doi:10.1097/SLA.0000000000003833.
   PubMed Web of Science ®Google Scholar
• Howat WJ, Lewis A, Jones P, Kampf C, Pontén F, Van Der Loos CM, Gray N, Womack C, Warford A. Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Methods. 2014;70(1):34–38. doi:10.1016/j.ymeth.2014.01.018.
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi:10.1093/annonc/mdy495.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209. doi:10.1038/nature13480.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Lee J, Nebozhyn M, Kim K-M, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–456. doi:10.1038/nm.3850.
   PubMed Web of Science ®Google Scholar
• Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782. doi:10.1038/s41587-019-0114-2.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662–680.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri3862.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021;18(8):473–487. doi:10.1038/s41571-021-00492-2.
   PubMed Web of Science ®Google Scholar
•  FGFR Inhibitor Stymies Gastric Cancer. Cancer Discov. 2021;11(5):OF3. doi:10.1158/2159-8290.CD-NB2021-0312.
   Google Scholar
• Kim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–1458. doi:10.1038/s41591-018-0101-z.
   PubMed Web of Science ®Google Scholar
• Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30(9):1479–1486. doi:10.1093/annonc/mdz197.
   PubMed Web of Science ®Google Scholar
• Cao D, Xu H, Xu X, Guo T, Ge W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology. 2019;8(9):e1629258. doi:10.1080/2162402X.2019.1629258.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. doi:10.1056/NEJMc1713444.
   PubMed Web of Science ®Google Scholar
• Andor N, Maley CC, Ji HP. Genomic instability in cancer: teetering on the limit of tolerance. Cancer Res. 2017;77(9):2179–2185. doi:10.1158/0008-5472.CAN-16-1553.
   PubMed Web of Science ®Google Scholar
• Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355(6322):eaaf8399. doi:10.1126/science.aaf8399.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461. doi:10.1016/j.ccell.2015.03.001.
   PubMed Web of Science ®Google Scholar
• van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–232. doi:10.1038/s41568-019-0235-4
   PubMed Web of Science ®Google Scholar